Search

Your search keyword '"Hasanov, Elshad"' showing total 130 results
Start Over Author "Hasanov, Elshad"
130 results on '"Hasanov, Elshad"'

4. Perioperative nivolumab monotherapy versus nivolumab plus ipilimumab in resectable hepatocellular carcinoma: a randomised, open-label, phase 2 trial

Author

Kaseb, Ahmed Omar, Hasanov, Elshad, Cao, Hop Sanderson Tran, Xiao, Lianchun, Vauthey, Jean-Nicolas, Lee, Sunyoung S, Yavuz, Betul Gok, Mohamed, Yehia I, Qayyum, Aliya, Jindal, Sonali, Duan, Fei, Basu, Sreyashi, Yadav, Shalini S, Nicholas, Courtney, Sun, Jing Jing, Singh Raghav, Kanwal Pratap, Rashid, Asif, Carter, Kristen, Chun, Yun Shin, Tzeng, Ching-Wei David, Sakamuri, Divya, Xu, Li, Sun, Ryan, Cristini, Vittorio, Beretta, Laura, Yao, James C, Wolff, Robert A, Allison, James Patrick, and Sharma, Padmanee

Published
2022
Full Text
View/download PDF

5. Association of genomic alterations with clinical outcomes following lutetium-177-PSMA vipivotide tetraxetan in men with metastatic castrate-resistant prostate cancer.

Author

Gauntner, Timothy, primary, Gheeya, Jinesh S., additional, Khorasanchi, Adam, additional, Xu, Menglin, additional, Hasanov, Elshad, additional, Collier, Katharine A., additional, Meng, Lingbin, additional, Zimmerman, Danielle Elise, additional, Wang, Peng, additional, Folefac, Edmund, additional, Monk, Paul, additional, Mortazavi, Amir, additional, Clinton, Steven K., additional, and Yang, Yuanquan (Aaron), additional

Published
2024
Full Text
View/download PDF

6. Phase 1b/2 study of combination 177Lu girentuximab plus cabozantinib and nivolumab in treatment naive patients with advanced clear cell RCC.

Author

Jonasch, Eric, primary, Hasanov, Elshad, additional, Flynt, Lesley, additional, Hwang, Hyunsoo, additional, Tidwell, Rebecca Slack, additional, Brooks, Roserika, additional, Wood, Lauren Michelle, additional, Solley, Travis, additional, Mack, Dahlia, additional, Yamamura, Yuko, additional, and Venkatesan, Aradhana M., additional

Published
2024
Full Text
View/download PDF

7. Germline genetic variants in cancers of the bladder, renal pelvis, ureter, or urethra.

Author

Kamau, Kent, primary, Byrne, Lindsey, additional, Sundi, Debasish, additional, Wang, Shang-Jui, additional, Yang, Yuanquan (Aaron), additional, Meng, Lingbin, additional, Wang, Peng, additional, Zimmerman, Danielle Elise, additional, Hasanov, Elshad, additional, Folefac, Edmund, additional, Monk, Paul, additional, Clinton, Steven K., additional, Mortazavi, Amir, additional, and Collier, Katharine A., additional

Published
2024
Full Text
View/download PDF

10. Serologic, radiographic, and tissue-based markers associated with major pathologic response after treatment with neoadjuvant immunotherapy in patients with resectable hepatocellular carcinoma.

Author

LaPelusa, Michael Brian, primary, Chamseddine, Shadi, additional, Xiao, Lianchun, additional, Hasanov, Elshad, additional, Bhosale, Priya, additional, Abugabal, Yehia I., additional, Gok Yavuz, Betul, additional, Yadav, Shalini S., additional, Tran Cao, Hop Sanderson, additional, Xu, Li, additional, Hu, Zishuo Ian, additional, Lee, Sunyoung S., additional, Sakamuri, Divya, additional, Curran, Michael A., additional, Jindal, Sonali, additional, Duda, Gabriel Dan, additional, Sharma, Padmanee, additional, Qayyum, Aliya, additional, and Kaseb, Ahmed Omar, additional

Published
2024
Full Text
View/download PDF

11. 523 Nivolumab and ipilimumab in patients with metastatic non-clear cell renal cell carcinoma at MD Anderson Cancer Center

Author

Khandelwal, Jaanki, primary, Surasi, Devaki S, additional, Klimkowsky, Sergio P, additional, Wilson, Nathaniel, additional, Moussa, Mohammad J, additional, Campbell, Matthew, additional, Shah, Amishi, additional, Jonasch, Eric, additional, Hahn, Andrew, additional, Hasanov, Elshad, additional, Gao, Jianjun, additional, Goswami, Sangeeta, additional, Msaouel, Pavlos, additional, Rao, Priya, additional, Sircar, Kanishka, additional, Tannir, Nizar, additional, and Alhalabi, Omar, additional

Published
2023
Full Text
View/download PDF

13. Supplementary Data 1 from SETD2 Loss and ATR Inhibition Synergize to Promote cGAS Signaling and Immunotherapy Response in Renal Cell Carcinoma

Author

Liu, Xian-De, primary, Zhang, Yan-Ting, primary, McGrail, Daniel J., primary, Zhang, Xuesong, primary, Lam, Truong, primary, Hoang, Anh, primary, Hasanov, Elshad, primary, Manyam, Ganiraju, primary, Peterson, Christine B., primary, Zhu, Haifeng, primary, Kumar, Shwetha V., primary, Akbani, Rehan, primary, Pilie, Patrick G., primary, Tannir, Nizar M., primary, Peng, Guang, primary, and Jonasch, Eric, primary

Published
2023
Full Text
View/download PDF

14. Data from SETD2 Loss and ATR Inhibition Synergize to Promote cGAS Signaling and Immunotherapy Response in Renal Cell Carcinoma

Author

Liu, Xian-De, primary, Zhang, Yan-Ting, primary, McGrail, Daniel J., primary, Zhang, Xuesong, primary, Lam, Truong, primary, Hoang, Anh, primary, Hasanov, Elshad, primary, Manyam, Ganiraju, primary, Peterson, Christine B., primary, Zhu, Haifeng, primary, Kumar, Shwetha V., primary, Akbani, Rehan, primary, Pilie, Patrick G., primary, Tannir, Nizar M., primary, Peng, Guang, primary, and Jonasch, Eric, primary

Published
2023
Full Text
View/download PDF

15. Advances in non‐clear cell renal cell carcinoma management: From heterogeneous biology to treatment options.

Author

Wilson, Nathaniel R., Acikgoz, Yusuf, and Hasanov, Elshad

Subjects
BIOLOGY, IMMUNE checkpoint inhibitors, PROTEIN-tyrosine kinase inhibitors, THERAPEUTICS, CANCER chemotherapy, RENAL cell carcinoma, THYROID cancer
Abstract

Non‐clear cell renal cell carcinoma (nccRCC) makes up nearly one quarter of all RCC subtypes, commonly impacts younger patients, and is often metastatic at presentation. Compared to clear‐cell RCC (ccRCC), nccRCC typically has a worse prognosis in the metastatic setting, with overall survival durations that are ~10 months shorter. The nccRCC consists of a wide range of different histological subtypes, the majority of which are composed of papillary, chromophobe, renal medullary carcinoma, translocation RCC, collecting duct carcinoma and unclassified RCC. Most clinical trials have either excluded or only included small numbers of patients with nccRCC; owing to the lack of prospective studies focusing on this population, data on response rates and survival outcomes are lacking. NccRCC treatment is a nascent field with various therapeutic modalities and combinations under investigation, often based on data extrapolated from therapeutic studies in ccRCC. We herein review the use and outcomes of cytotoxic chemotherapy, various combination modalities of tyrosine kinase inhibitors and immune checkpoint inhibitors, and targeted agents. We discuss active ongoing clinical trials for patients with nccRCC and future directions in the treatment of this rare disease. Historically, treatment for nccRCC has been adopted from the standard of care for patients with ccRCC, although these treatments are less effective in the nccRCC population. As we begin to understand the underlying biology of these tumors, clinical trials have been able to slowly accrue and include more patients with various subtypes of nccRCC. There remains much room for improvement in this area of need, but there is hope on the horizon. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

17. SETD2 Loss and ATR Inhibition Synergize to Promote cGAS Signaling and Immunotherapy Response in Renal Cell Carcinoma

Author

Liu, Xian-De, primary, Zhang, Yan-Ting, additional, McGrail, Daniel J., additional, Zhang, Xuesong, additional, Lam, Truong, additional, Hoang, Anh, additional, Hasanov, Elshad, additional, Manyam, Ganiraju, additional, Peterson, Christine B., additional, Zhu, Haifeng, additional, Kumar, Shwetha V., additional, Akbani, Rehan, additional, Pilie, Patrick G., additional, Tannir, Nizar M., additional, Peng, Guang, additional, and Jonasch, Eric, additional

Published
2023
Full Text
View/download PDF

18. STARLITE 1: Phase 1b/2 study of combination 177Lu girentuximab plus cabozantinib and nivolumab in treatment naïve patients with advanced clear cell RCC

Author

Hasanov, Elshad, primary, Flynt, Lesley, additional, Slack Tidwell, Rebecca, additional, Hwang, Hyunsoo, additional, Brooks, Roserika, additional, King, Lauren, additional, Solley, Travis, additional, Syed, Mashaal, additional, Yamamura, Yuko, additional, Hayward, Colin, additional, Venkatesan, Aradhana M, additional, and Jonasch, Eric, additional

Published
2023
Full Text
View/download PDF

19. A multi-center, open-label phase II study of lenvatinib plus pembrolizumab (LEAP) in patients with renal cell carcinoma with brain metastasis previously treated with immune checkpoint blockade.

Author

Hasanov, Elshad, Hammers, Hans J., George, Daniel J., Rini, Brian I., Beckermann, Katy, Palmer, Joshua David, Mortazavi, Amir, Brooks, Roserika, Solley, Travis, Wood, Lauren Michelle, Haas, Naomi B., McDermott, David F., Vaishampayan, Ulka N., and Jonasch, Eric

Published
2024
Full Text
View/download PDF

21. Abstract 4153: SETD2 loss and ATR inhibition synergistically promote cGAS signaling and immunotherapy response in renal cell carcinoma

Author

Liu, Xiande, primary, Zhang, Yanting, additional, Zhang, Xuesong, additional, McGrail, Daniel, additional, Lam, Truong, additional, Hoang, Anh, additional, Hasanov, Elshad, additional, Manyam, Ganiraju, additional, Peterson, Christine B., additional, Zhu, Haifeng, additional, Kumar, Shwetha V., additional, Akbani, Rehan, additional, Tannir, Nizar M., additional, Peng, Guang, additional, and Jonasch, Eric, additional

Published
2023
Full Text
View/download PDF

22. Abstract 5788: Single-cell and spatial transcriptomic mapping of human renal cell carcinoma brain metastases uncovers actionable immune-resistance targets

Author

Hasanov, Elshad, primary, Lam, Truong Nguyen Anh, additional, Lin, Jerome, additional, Reville, Patrick K., additional, Hasanov, Merve, additional, Casasent, Anna K., additional, Shih, David, additional, Hanalioglu, Sahin, additional, Bilen, Mehmet Asim, additional, Alhalabi, Omar, additional, Babaoglu, Berrin, additional, Baylarov, Baylar, additional, Osunkoya, Adeboye O., additional, Norberg, Lisa M., additional, Gumin, Joy, additional, Tran, Tuan M., additional, Li, Jianzhuo, additional, Hoang, Anh G., additional, Chancoco, Haidee D., additional, Kerrigan, Brittany C. Parker, additional, Thompson, Erika J., additional, Kim, Betty YS, additional, Suki, Dima, additional, Mut, Melike, additional, Soylemezoglu, Figen, additional, Genovese, Giannicola, additional, Akdemir, Kadir C., additional, Tawbi, Hussain A., additional, Tannir, Nizar M., additional, McAllister, Florencia, additional, Davies, Michael A., additional, Sharma, Padmanee, additional, Huse, Jason, additional, Lang, Frederick, additional, Navin, Nicholas, additional, and Jonasch, Eric, additional

Published
2023
Full Text
View/download PDF

23. Phase 1b/2 study of combination 177Lu girentuximab plus cabozantinib and nivolumab in treatment naïve patients with advanced clear cell RCC.

Author

Hasanov, Elshad, primary, Flynt, Lesley, additional, Slack Tidwell, Rebecca, additional, Hwang, Hyunsoo, additional, Brooks, Roserika, additional, King, Lauren Michelle, additional, Solley, Travis, additional, Mack, Dahlia, additional, Yamamura, Yuko, additional, Hayward, Colin, additional, Venkatesan, Aradhana M., additional, and Jonasch, Eric, additional

Published
2023
Full Text
View/download PDF

24. Immune Checkpoint Therapy Combinations in Adult Advanced MiT Family Translocation Renal Cell Carcinomas

Author

Alhalabi, Omar, primary, Thouvenin, Jonathan, additional, Négrier, Sylvie, additional, Vano, Yann-Alexandre, additional, Campedel, Luca, additional, Hasanov, Elshad, additional, Bakouny, Ziad, additional, Hahn, Andrew W, additional, Bilen, Mehmet Asim, additional, Msaouel, Pavlos, additional, Choueiri, Toni K, additional, Viswanathan, Srinivas R, additional, Sircar, Kanishka, additional, Albiges, Laurence, additional, Malouf, Gabriel G, additional, and Tannir, Nizar M, additional

Published
2023
Full Text
View/download PDF

26. Efficacy of Cabozantinib in Metastatic MiT Family Translocation Renal Cell Carcinomas

Author

Thouvenin, Jonathan, primary, Alhalabi, Omar, additional, Carlo, Maria, additional, Carril-Ajuria, Lucia, additional, Hirsch, Laure, additional, Martinez-Chanza, Nieves, additional, Négrier, Sylvie, additional, Campedel, Luca, additional, Martini, Dylan, additional, Borchiellini, Delphine, additional, Chahoud, Jad, additional, Lodi, Massimo, additional, Barthélémy, Philippe, additional, Hasanov, Elshad, additional, Hahn, Andrew W, additional, Gil, Thierry, additional, Viswanathan, Srinivas R, additional, Bakouny, Ziad, additional, Msaouel, Pavlos, additional, Asim Bilen, Mehmet, additional, Choueiri, Toni K, additional, Albiges, Laurence, additional, Tannir, Nizar M, additional, and Malouf, Gabriel G, additional

Published
2022
Full Text
View/download PDF

28. An interdisciplinary consensus on the management of brain metastases in patients with renal cell carcinoma

Author

Hasanov, Elshad, primary, Yeboa, Debra Nana, additional, Tucker, Mathew D., additional, Swanson, Todd A., additional, Beckham, Thomas Hendrix, additional, Rini, Brian, additional, Ene, Chibawanye I., additional, Hasanov, Merve, additional, Derks, Sophie, additional, Smits, Marion, additional, Dudani, Shaan, additional, Heng, Daniel Y. C., additional, Brastianos, Priscilla K., additional, Bex, Axel, additional, Hanalioglu, Sahin, additional, Weinberg, Jeffrey S., additional, Hirsch, Laure, additional, Carlo, Maria I., additional, Aizer, Ayal, additional, Brown, Paul David, additional, Bilen, Mehmet Asim, additional, Chang, Eric Lin, additional, Jaboin, Jerry, additional, Brugarolas, James, additional, Choueiri, Toni K., additional, Atkins, Michael B., additional, McGregor, Bradley A., additional, Halasz, Lia M., additional, Patel, Toral R., additional, Soltys, Scott G., additional, McDermott, David F., additional, Elder, James Bradley, additional, Baskaya, Mustafa K., additional, Yu, James B., additional, Timmerman, Robert, additional, Kim, Michelle Miran, additional, Mut, Melike, additional, Markert, James, additional, Beal, Kathryn, additional, Tannir, Nizar M., additional, Samandouras, George, additional, Lang, Frederick F., additional, Giles, Rachel, additional, and Jonasch, Eric, additional

Published
2022
Full Text
View/download PDF

29. Perioperative nivolumab monotherapy versus nivolumab plus ipilimumab in resectable hepatocellular carcinoma:a randomised, open-label, phase 2 trial

Author

Kaseb, Ahmed Omar, Hasanov, Elshad, Cao, Hop Sanderson Tran, Xiao, Lianchun, Vauthey, Jean Nicolas, Lee, Sunyoung S., Yavuz, Betul Gok, Mohamed, Yehia I., Qayyum, Aliya, Jindal, Sonali, Duan, Fei, Basu, Sreyashi, Yadav, Shalini S., Nicholas, Courtney, Sun, Jing Jing, Singh Raghav, Kanwal Pratap, Rashid, Asif, Carter, Kristen, Chun, Yun Shin, Tzeng, Ching Wei David, Sakamuri, Divya, Xu, Li, Sun, Ryan, Cristini, Vittorio, Beretta, Laura, Yao, James C., Wolff, Robert A., Allison, James Patrick, Sharma, Padmanee, Kaseb, Ahmed Omar, Hasanov, Elshad, Cao, Hop Sanderson Tran, Xiao, Lianchun, Vauthey, Jean Nicolas, Lee, Sunyoung S., Yavuz, Betul Gok, Mohamed, Yehia I., Qayyum, Aliya, Jindal, Sonali, Duan, Fei, Basu, Sreyashi, Yadav, Shalini S., Nicholas, Courtney, Sun, Jing Jing, Singh Raghav, Kanwal Pratap, Rashid, Asif, Carter, Kristen, Chun, Yun Shin, Tzeng, Ching Wei David, Sakamuri, Divya, Xu, Li, Sun, Ryan, Cristini, Vittorio, Beretta, Laura, Yao, James C., Wolff, Robert A., Allison, James Patrick, and Sharma, Padmanee

Abstract

Background: Hepatocellular carcinoma has high recurrence rates after surgery; however, there are no approved standard-of-care neoadjuvant or adjuvant therapies. Immunotherapy has been shown to improve survival in advanced hepatocellular carcinoma; we therefore aimed to evaluate the safety and tolerability of perioperative immunotherapy in resectable hepatocellular carcinoma. Methods: In this single-centre, randomised, open-label, phase 2 trial, patients with resectable hepatocellular carcinoma were randomly assigned (1:1) to receive 240 mg of nivolumab intravenously every 2 weeks (for up to three doses before surgery at 6 weeks) followed in the adjuvant phase by 480 mg of nivolumab intravenously every 4 weeks for 2 years, or 240 mg of nivolumab intravenously every 2 weeks (for up to three doses before surgery) plus one dose of 1 mg/kg of ipilimumab intravenously concurrently with the first preoperative dose of nivolumab, followed in the adjuvant phase by 480 mg of nivolumab intravenously every 4 weeks for up to 2 years plus 1 mg/kg of ipilimumab intravenously every 6 weeks for up to four cycles. Patients were randomly assigned to the treatment groups by use of block randomisation with a random block size. The primary endpoint was the safety and tolerability of nivolumab with or without ipilimumab. Secondary endpoints were the proportion of patients with an overall response, time to progression, and progression-free survival. This trial is registered with ClinicalTrials.gov (NCT03222076) and is completed. Findings: Between Oct 30, 2017, and Dec 3, 2019, 30 patients were enrolled and 27 were randomly assigned: 13 to nivolumab and 14 to nivolumab plus ipilimumab. Grade 3–4 adverse events were higher with nivolumab plus ipilimumab (six [43%] of 14 patients) than with nivolumab alone (three [23%] of 13). The most common treatment-related adverse events of any grade were increased alanine aminotransferase (three [23%] of 13 patients on nivolumab vs seven [50%] of 14 pa

Published
2022

31. Immuno-oncology (IO) combinations +/- VEGF targeted therapy (VEGF TT) in patients (pts) with advanced mit family translocation renal cell carcinomas (tRCC): Results from an international multicenter study.

Author

Alhalabi, Omar, primary, Thouvenin, Jonathan, additional, Negrier, Sylvie, additional, Vano, Yann-Alexandre, additional, Campedel, Luca, additional, Hasanov, Elshad, additional, Bakouny, Ziad, additional, Hahn, Andrew Warren, additional, Bilen, Mehmet Asim, additional, Choueiri, Toni K., additional, Viswanathan, Srinivas Raghavan, additional, Sircar, Kanishka, additional, Albiges, Laurence, additional, Malouf, Gabriel, additional, and Tannir, Nizar M., additional

Published
2022
Full Text
View/download PDF

32. Safety and differential clinical activity of nivolumab plus ipilimumab (nivo-ipi) in patients (pts) with non-clear cell renal cell carcinoma (nccRCC).

Author

Alhalabi, Omar, primary, Wilson, Nathaniel, additional, Ajufo, Helen, additional, Lehner, Michael, additional, Hasanov, Elshad, additional, Campbell, Matthew T, additional, Shah, Amishi Yogesh, additional, Wang, Jennifer, additional, Jonasch, Eric, additional, Araujo, John C., additional, Wang, Jianbo, additional, Gao, Jianjun, additional, Goswami, Sangeeta, additional, Msaouel, Pavlos, additional, and Tannir, Nizar M., additional

Published
2022
Full Text
View/download PDF

33. Current Landscape and Future Directions of Biomarkers for Immunotherapy in Hepatocellular Carcinoma

Author

Gok Yavuz,Betul, Hasanov,Elshad, Lee,Sunyoung S, Mohamed,Yehia I, Curran,Michael A, Koay,Eugene J, Cristini,Vittorio, and Kaseb,Ahmed O

Subjects
Journal of Hepatocellular Carcinoma
Abstract

Betul Gok Yavuz,1 Elshad Hasanov,2 Sunyoung S Lee,1 Yehia I Mohamed,1 Michael A Curran,3 Eugene J Koay,4 Vittorio Cristini,5,6 Ahmed O Kaseb1 1Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; 2Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; 3Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; 4Department of Gastrointestinal Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; 5Mathematics in Medicine Program, Houston Methodist Research Institute, Houston, TX, USA; 6Department of Imaging Physics, University of Texas MD Anderson Cancer Center, Houston, TX, USACorrespondence: Ahmed O Kaseb Email akaseb@mdanderson.orgAbstract: Hepatocellular carcinoma (HCC) is the most common liver cancer and one of the leading causes of cancer-related deaths in the world. Multiple immunotherapeutic approaches have been investigated to date, and immunotherapy has become the new standard of care therapy in HCC. However, the current role of immunotherapy in HCC remains non-curative. Given this context, a high priority for oncology is understanding the biomarkers that predict clinical response to immunotherapy, have the potential to improve patient selection to maximize the clinical benefit, and spare unnecessary toxicity. In this review, we summarize the key predictive and prognostic biomarkers investigated in immunotherapy clinical trials in HCC and the emerging biomarkers to serve as a roadmap for future clinical trials. Biomarkers from tumoral tissues including PDL-1 expression, tissue infiltrating lymphocytes, tumor mutational burden (TMB) and specific immune signatures, and from peripheral blood including neutrophil-to-lymphocytes ratio, platelet-to-lymphocytes ratio, circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), and specific cytokines, along with gut microbiota are among the studied biomarkers to date in the HCC era. More integrative approaches, including mathematical biomarkers to predict immunotherapy outcomes, are yet to be studied in HCC.Keywords: hepatocellular carcinoma, immunotherapy, biomarker

Published
2021

34. 241 Immune checkpoint blockade (ICB) in brain metastases (BM) from advanced small cell urothelial cancer (aSCUC)

Author

Wilson, Nathaniel, primary, Alhalabi, Omar, additional, Hasanov, Elshad, additional, Xiao, Lianchun, additional, Papadopoulos, John, additional, Campbell, Matthew, additional, Shah, Amishi, additional, Gao, Jianjun, additional, Corn, Paul, additional, Aparicio, Ana, additional, Wang, Jennifer, additional, Czerniak, Bogdan, additional, Guo, Charles, additional, Logothetis, Christopher, additional, Li, Jing, additional, Choi, Seungtaek, additional, Tang, Chad, additional, Tannir, Nizar, additional, and Siefker-Radtke, Arlene, additional

Published
2021
Full Text
View/download PDF

38. Outcomes of patients with intermediate‐risk or poor‐risk metastatic renal cell carcinoma who received their first cycle of nivolumab and ipilimumab in the hospital because of symptomatic disease: The MD Anderson Cancer Center experience

Author

Alhalabi, Omar, primary, Hasanov, Elshad, additional, Wilson, Nathaniel R., additional, Araujo, John, additional, Wang, Jianbo, additional, Campbell, Matthew T., additional, Goswami, Sangeeta, additional, Shah, Amishi Y., additional, Gao, Jianjun, additional, Msaouel, Pavlos, additional, and Tannir, Nizar M., additional

Published
2021
Full Text
View/download PDF

39. Efficacy of cabozantinib in advanced MiT family translocation renal cell carcinomas (TRCC).

Author

Thouvenin, Jonathan, primary, Alhalabi, Omar, additional, Hirsch, Laure, additional, Hasanov, Elshad, additional, Barthelemy, Philippe, additional, Martini, Dylan J., additional, Campedel, Lucas, additional, Amrane, Karim, additional, Borchiellini, Delphine, additional, Chahoud, Jad, additional, Bakouny, Ziad, additional, Ravi, Praful, additional, Viswanathan, Srinivas Raghavan, additional, Bilen, Mehmet Asim, additional, Choueiri, Toni K., additional, Tannir, Nizar M., additional, and Malouf, Gabriel G., additional

Published
2021
Full Text
View/download PDF

41. 441 Outcomes of patients with metastatic renal cell carcinoma with intermediate- or poor-risk symptomatic disease who received their first cycle of nivolumab and ipilimumab while being hospitalized

Author

Alhalabi, Omar, primary, Hasanov, Elshad, additional, Araujo, John, additional, Wang, Jianbo, additional, Campbell, Matthew, additional, Goswami, Sangeeta, additional, Shah, Amishi, additional, Gao, Jianjun, additional, Msaouel, Pavlos, additional, and Tannir, Nizar, additional

Published
2020
Full Text
View/download PDF

42. Analysis of chemotherapy-related modulation of the immune microenvironment in muscle invasive bladder cancer.

Author

Hasanov, Elshad, primary, Tabayoyong, William, additional, Chen, Jianfeng, additional, Yang, Guoliang, additional, Nie, Fengqi, additional, Meng, Jieru, additional, Hoang, Anh, additional, Zhu, Yueting, additional, Efstathiou, Eleni, additional, Bondaruk, Jolan, additional, Wang, Wei-Lien, additional, Guo, Charles, additional, Zhang, Miao, additional, Czerniak, Bogdan, additional, Logothetis, Christopher, additional, Kamat, Ashish M., additional, and Gao, Jianjun, additional

Published
2020
Full Text
View/download PDF

43. Evaluation of brain metastasis in JAVELIN Renal 101: Efficacy of avelumab + axitinib (A+Ax) versus sunitinib (S).

Author

Jonasch, Eric, primary, Hasanov, Elshad, additional, Motzer, Robert J., additional, Hariharan, Subramanian, additional, Choueiri, Toni K., additional, Huang, Bo, additional, Haanen, John B. A. G., additional, Albiges, Laurence, additional, Venugopal, Balaji, additional, Schmidinger, Manuela, additional, Larkin, James M. G., additional, Grimm, Marc-Oliver, additional, Negrier, Sylvie, additional, Wang, Jing, additional, Mariani, Mariangela, additional, Chudnovsky, Aleksander, additional, di Pietro, Alessandra, additional, and Rini, Brian I., additional

Published
2020
Full Text
View/download PDF

46. Effects of tamoxifen on urinary incontinence

Author

Hasanov, Elshad, Hasanov, Merve, Kuria, Issa M., Hasanov, Rovshan, Rzazade, Reshad, Jonasch, Eric, Altundag, Kadri, and İç Hastalıkları

Subjects
urinary incontinence, tamoxifen, Antineoplastic Agents, Hormonal, Dose-Response Relationship, Drug, Breast Neoplasms, breast cancer, Quality of Life, Humans, Female, Clinical Case Report, skin and connective tissue diseases, hormones, hormone substitutes, and hormone antagonists, Research Article, Aged
Abstract

Rationale: Tamoxifen has been used in women with hormone receptor-positive breast cancer and has been shown to successfully reduce both recurrence and mortality. On the contrary, long-term use of tamoxifen has hormone-related urogenital side effects which decrease the quality of life of the patients. Patient concerns: In this case report, we present a breast cancer patient receiving tamoxifen who developed urinary incontinence; we discuss the effects of tamoxifen on urinary incontinence, which decreases quality of life of the patients who were evaluated in our clinic. Diagnoses: Breast cancer, urinary incontinence. Interventions: Temporarily discontinuing tamoxifen. Outcomes: Urinary incontinence resolved. Lessons: Based on the case we reported and literature, estrogen can cause a dose-dependent increase in incontinence, but more preclinical and clinical studies of both estrogen and SERMs are needed to support this notion; given the fact that some small-scale clinical studies have not proven a direct relationship between tamoxifen and urinary incontinence. We suggest that clinicians faced with the issue should temporarily stop usage of the drug once the complaint of urinary incontinence arises.

Published
2017

Catalog

Books, media, physical & digital resources
See catalog results